MEI Pharma (United States)

ROR: 02bgfrc80

OpenAlex ID: I4210115926

Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes

2017 · Guillermo Garcia‐Manero, Guillermo Montalban‐Bravo, et al. · Cancer · 106

PDF

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study

2019 · Guillermo Garcia-Manero, Yasmin Abaza, et al. · Blood Advances · 87

PDF

Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies

2017 · Yasmin M. Abaza, Tapan M. Kadia, et al. · Cancer · 58

PDF

Phase 1, open‐label, dose escalation, safety, and pharmacokinetics study of ME‐344 as a single agent in patients with refractory solid tumors

2014 · Johanna C. Bendell, Manish R. Patel, et al. · Cancer · 31

PDF

Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial

2022 · John M Pagel, Jacob D Soumerai, et al. · The Lancet Oncology · 28

Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers

2018 · Ofir Moreno, Todd Butler, et al. · Clinical Therapeutics · 28

PDF

Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers

2017 · Jennifer R. Diamond, Barbara Goff, et al. · Investigational New Drugs · 25

Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)

2015 · Guillermo Garcia-Manero, Ehab Atallah, et al. · Blood · 25

Interferon-gamma signaling promotes melanoma progression and metastasis

2022 · Bo Zhou, Jayati Basu, et al. · Oncogene · 23

PDF

A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit

2016 · Guillermo Garcia Manero, Ehab Atallah, et al. · Blood · 20

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro

2023 · Katie H. Hurrish, Yongwei Su, et al. · Biochemical Pharmacology · 18

A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy

2019 · Fevzi F. Yalniz, Jesus G. Berdeja, et al. · British Journal of Haematology · 18

Initial results of a dose escalation study of a selective and structurally differentiated PI3Kδ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

2018 · Jacob Drobnyk Soumerai, John M. Pagel, et al. · Journal of Clinical Oncology · 18

Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase δ (PI3Kδ) in Animal and B-Cell Lymphoma Models

2019 · Ofir Moreno, Jamie Wood · Targeted Oncology · 16

PDF

Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kδ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies

2018 · Andrew D. Zelenetz, Jacob D. Soumerai, et al. · Blood · 14

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies

2024 · Matthew S. Davids, Danielle M. Brander, et al. · Blood Advances · 12

PDF

Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL).

2019 · Andrew David Zelenetz, Deepa Jagadeesh, et al. · Journal of Clinical Oncology · 12

Activating Transcription Factor 3 Expression as a Marker of Response to the Histone Deacetylase Inhibitor Pracinostat

2016 · Dhanya Sooraj, Dakang Xu, et al. · Molecular Cancer Therapeutics · 12

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors

2013 · Shubham Pant, Howard A. Burris, et al. · Investigational New Drugs · 11

PDF

Tolerability and durable respones of the PI3Kδ inhibitor ME-401 administered on an intermittent schedule in relapsed/refractory (R/R) follicular lymphoma (FL) and other B-cell malignancies.

2020 · Andrew David Zelenetz, Nishitha Reddy, et al. · Journal of Clinical Oncology · 10

Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas

2024 · Jacob D. Soumerai, Catherine S. Diefenbach, et al. · British Journal of Haematology · 7

PDF

Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL.

2022 · Andrew David Zelenetz, Wojciech Jurczak, et al. · Journal of Clinical Oncology · 6

Phase II study of lower-dose pracinostat plus azacitidine safety and efficacy in patients with high/very high-risk myelodysplastic syndromes.

2020 · Ehab L. Atallah, Samer K. Khaled, et al. · Journal of Clinical Oncology · 6

Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

2022 · Andrew D. Zelenetz, Wojciech Jurczak, et al. · Blood · 5

Coastal: A Phase 3 Study of the PI3Kδ Inhibitor Zandelisib with Rituximab (R) Versus Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

2021 · Wojciech Jurczak, Pier Luigi Luigi Zinzani, et al. · Blood · 5

Works count: 61

Citation count: 943